What monitoring is recommended after starting denosumab?

• A. Check serum calcium within 1–2 weeks after the first dose; monitor for hypocalcemia; ensure adequate calcium and vitamin D; periodic DEXA to assess response.
• B. Monitor liver enzymes monthly.
• C. No monitoring required.
• D. Periodic bone biopsy.

Answer: (A)

Denosumab works by blocking RANKL, which keeps osteoclasts from breaking down bone. That action can lower calcium levels in the blood, especially in the first weeks after the first dose and in people with low calcium or vitamin D or with kidney issues. Because of this risk, the most important immediate monitoring after starting therapy is to check a serum calcium level within 1–2 weeks of the first dose, so any drop can be detected early and managed.

To prevent hypocalcemia, it’s essential to ensure adequate calcium and vitamin D intake or supplementation. If calcium is low, treatment can include calcium and vitamin D and adjustment of therapy as needed. Beyond safety, you also want to track how well the treatment is working for bone health. Denosumab reduces bone resorption, so measuring bone density periodically with DEXA helps assess the patient’s response over time.

Liver enzyme monitoring isn’t routinely required for denosumab, and bone biopsy isn’t used for routine monitoring. No monitoring at all wouldn’t catch potential hypocalcemia or allow you to gauge effectiveness.